

June 30, 2016

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Sub: Press Release


Please find attached press release issued by the Company titled:

**Strides Shasun announces successful completion of US FDA inspection at its
Oral Dosage Facility in Bangalore**

Yours faithfully
For **STRIDES SHASUN LIMITED**



Badree Komandur
Group CFO & Company Secretary





Press Release

Thursday, June 30, 2016

Strides Shasun Limited
Star II, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore

Zero 483's Status

Bangalore, June 30, 2016 Strides Shasun Limited today announced successful completion of USFDA inspection at its flagship Oral Dosage Facility in Bangalore with "Zero 483s".

The Audit was carried out related to a product filed from the new semi solids block from where the Company has made a series of filings.

With the recently closed Establishment Inspection Report (EIR) announced on June 7, 2016, the entire facility is now US FDA compliant.

The Oral Dosage facility (KRS Gardens facility) in Bangalore manufactures oral dosage forms including tablets, capsules (both hard gelatine and soft gelatine), ointments and liquids. The manufacturing plant supports important current and future submissions for the US Market

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.



The Company has global manufacturing foot print with 14 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides Shasun</u> Badree Komandur, Group CFO +91 80 6784 0747 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
---	---

